Venture&Growth Archives - Gilde Healthcare

Menu
Menu
Home

latest news
Venture&Growth

Gilde Healthcare haalt €600 miljoen op voor investeringen in zorginnovatie

€600 miljoen aan commitments van een gebalanceerde mix van internationale investeerders voor het nieuwe investeringssfonds Gilde Healthcare Venture&Growth VI Gilde Healthcare investeert in snelgroeiende bedrijven die betere zorg tegen lagere kosten mogelijk maken, ondersteund door de recent aangestelde Impact Council In drie jaar tijd haalt Gilde Healthcare ruim €1,5 miljard op, verdeeld over drie fondsen Gilde Healthcare kondigt vandaag een...
19 april 2023

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

test Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it’s the first and only device of its kind for people with symptomatic knee OA  More than 32 million people in the United States are affected by […]

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

test Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series A extension financing, raising a further EUR 31M, following the EUR 51M Series A financing in April 2021. The financing […]

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare

GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced that it has raised $45 million in a Series C financing led by Gilde Healthcare Partners with participation from existing institutional investors MVM Partners, MedTech Venture Partners, and...

Gilde Healthcare company FIRE1 raises $25 million to revolutionize heart failure home monitoring

Gilde Healthcare company FIRE1 today announced the close of a $25 million financing round led by new investors Andera Partners and Novo Holdings, with participation and ongoing support from existing investors Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, New Enterprise Associates and Seventure Partners. The financing provides FIRE1 with capital to accelerate the development of its novel remote monitoring solution to improve...

Gilde Healthcare leads $42 million growth financing round in medtech company Shoulder Innovations

Shoulder Innovations Inc. (SI), a Grand Rapids, Michigan based leader in the shoulder replacement implant market, announced closing on an oversubscribed $42 million Series D financing. SI is a commercial stage medical device company with an experienced team of successful innovators in the shoulder space. The financing was...

Gilde Healthcare company Big Health builds out its Leadership Team with the appointment of five key Executives

Big Health, creators of the leading digital treatments for mental health, has appointed five executives to its senior leadership team as the company enters the next phase in the growth of its business. This follows the company’s CEO transition in August 2022 to Arun Gupta, who was previously on the...

Gilde Healthcare company Volta medical secures €36M in Series B funding

Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced €36 million in new Series B funding, bringing the total capital raised to over €70 million. The funding round...

Gilde Healthcare company Adcendo Aps Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for...
Loading...
These were all messages
51f739d166